ICAGEN REPORTS INTERIM RESULTS OF TRIAL OF SCD TREATMENT

Icagen has announced that, following a planned interim safety, efficacy and futility analysis by an independent data monitoring committee (DMC) of a Phase III trial of ICA-17043 for the treatment of sickle cell disease (SCD), the DMC recommended that enrollment continue for patients on concurrent hydroxyurea therapy.

Approximately half of the patients enrolled in the study to date are on concurrent hydroxyurea therapy. For currently enrolled patients not on hydroxyurea, the DMC recommended that study drug be discontinued and that patients proceed to the end of study follow-up period. The DMC noted further that there were no specific safety issues identified. Finally, the DMC has requested additional data and will reconvene when these are available.